» Authors » Rachael W Sirianni

Rachael W Sirianni

Explore the profile of Rachael W Sirianni including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 581
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang W, Oh J, Zhang W, Aldrich C, Sirianni R, Elmquist W
J Pharmacol Exp Ther . 2025 Feb; 392(1):100014. PMID: 39893010
Histone deacetylase expression and activity are often dysregulated in central nervous system (CNS) tumors, providing a rationale for investigating histone deacetylase inhibitors (HDACIs) in selected brain tumor patients. Although many...
2.
Simmons A, Mihalek O, Bimonte Nelson H, Sirianni R, Stabenfeldt S
Front Biomater Sci . 2024 Oct; 3. PMID: 39450372
Sex as a biological variable has been recognized for decades to be a critical aspect of the drug development process, as differences in drug pharmacology and toxicity in female male...
3.
Zhang W, Oh J, Zhang W, Aldrich C, Sirianni R, Elmquist W
J Pharmacol Exp Ther . 2024 Feb; 389(1):96-105. PMID: 38409112
The deregulation of histone deacetylase (HDAC) expression is often seen in many cancers, and HDAC inhibitors have shown potency against a variety of cancer types. Panobinostat is a potent pan-HDAC...
4.
Fowler M, Riley C, Tomasson E, Mehta S, Grande-Allen J, Ballester L, et al.
Biomater Adv . 2023 Nov; 155:213646. PMID: 37918168
Leptomeningeal metastasis (LM) occurs when cancer cells infiltrate the subarachnoid space (SAS) and metastasize to the fibrous structures that surround the brain and spinal cord. These structures include the leptomeninges...
5.
Zhang W, Oh J, Zhang W, Rathi S, Larson J, Wechsler-Reya R, et al.
J Pharmacol Exp Ther . 2023 Oct; 387(3):315-327. PMID: 37827699
Achieving adequate exposure of the free therapeutic agent at the target is a critical determinant of efficacious chemotherapy. With this in mind, a major challenge in developing therapies for central...
6.
Heffernan J, McNamara J, Vernon B, Mehta S, Sirianni R
Biomater Sci . 2022 Jan; 10(3):819-833. PMID: 34994746
Glioblastoma (GBM) brain tumors contain a subpopulation of self-renewing multipotent Glioblastoma stem-like cells (GSCs) that are believed to drive the near inevitable recurrence of GBM. We previously engineered temperature responsive...
7.
Bell L, Fuentes A, Healey D, Chao R, Bakkar N, Sirianni R, et al.
Magn Reson Imaging . 2021 Oct; 85:217-221. PMID: 34715291
T relaxivity contrast imaging may serve as a potential imaging biomarker for amyotrophic lateral sclerosis (ALS) by noninvasively quantifying the tissue microstructure. In this preliminary longitudinal study, we investigated the...
8.
Chaudhuri S, Fowler M, Baker C, Stopka S, Regan M, Sablatura L, et al.
ACS Appl Mater Interfaces . 2021 Apr; 13(18):20960-20973. PMID: 33905245
Therapeutic development of histone deacetylase inhibitors (HDACi) has been hampered by a number of barriers to drug delivery, including poor solubility and inadequate tissue penetration. Nanoparticle encapsulation could be one...
9.
Prakapenka A, Quihuis A, Carson C, Patel S, Bimonte-Nelson H, Sirianni R
Front Behav Neurosci . 2021 Jan; 14:597690. PMID: 33424559
Hormone therapy that contains 17β-estradiol (E2) is used commonly for treatment of symptoms associated with menopause. E2 treatment has been shown to improve cognitive function following the decrease in ovarian...
10.
Prakapenka A, Pena V, Strouse I, Northup-Smith S, Schrier A, Ahmed K, et al.
Pharmaceutics . 2020 Dec; 12(12). PMID: 33348722
Exogenously administered 17β-estradiol (E2) can improve spatial learning and memory, although E2 also exerts undesired effects on peripheral organs. Clinically, E2 has been solubilized in cyclodextrin for intranasal administration, which...